[Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
Levels of matrix metalloproteinase (MMP-2) and endogenous inhibitors (TIMP-1,-2) in tumor and blood serum from patients with squamous-cell laryngeal carcinoma were studied. Immunohistochemical investigation showed much higher MMP-9 expression (76.9%) and TIMP-1 (100%) in tumor tussue than MMP-2 (23.8%) and TIMP-2 (33.3%). Therefore, MMP-9 and TIMP-1 levels in blood serum alone were assayed. TIMP-1 levels in serum from patients were significantly higher than those in healthy subjects (p=0.023). High TIMP-1 levels in blood serum were recorded in patients with stage III laryngeal carcinoma and differed significantly from control (p=0.009). However, no correlation was found between them and MMP concentration in blood serum, on the one hand, and tumor size, on the other. High TIMP-1 levels in blood serum were recorded in patients free from metastasis to regional lymph nodes (124.5+39.5 ng/ml); however, they were lower than in those with such metastases (102.7+10.9 ng/ml) and significantly lower than in healthy subjects (p=0.023). There was a correlation between MMP-9 expression in tumor tissue, on the one hand, and involvement of regional lymph nodes, on the other, (p=0.054). In blood serum from patients showing tumor regression by 75-100% after radiotherapy, TIMP-1 levels were higher than in those with relatively lower response to the same treatment (p=0.072). Hence, assay of TIMP-1 levels in blood serum and MMP-9 concentration in tumor tissue may be used for assessment of tumor processes alongside standard procedures. Moreover, the former may be instrumental in predicting laryngeal response to radiotherapy.
Klisho
E V
EV
Savenkova
O V
OV
Kondakova
I V
IV
Perel'muter
V M
VM
Choĭnzonov
E L
EL
Shishkin
D A
DA
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis* / Q000473:pathology; D005260:Female; D006801:Humans; D007822:Laryngeal Neoplasms / Q000175:diagnosis* / Q000473:pathology; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000032:analysis* / Q000097:blood; D020780:Matrix Metalloproteinase 9 / Q000032:analysis* / Q000097:blood; D008875:Middle Aged; D011379:Prognosis; D011836:Radiation Tolerance; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000032:analysis* / Q000097:blood; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000032:analysis* / Q000097:blood
D019715:Tissue Inhibitor of Metalloproteinase-1; D019716:Tissue Inhibitor of Metalloproteinase-2; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9